SNY - Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder | Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that Dupixent significantly reduced exacerbations.
The European Medicines Agency is reviewing the Dupixent application for uncontrolled COPD with type 2 inflammation; this application is based on results from the BOREAS trial.
Regeneron and Sanofi plan to submit the data from this replicate trial and results from the Phase 3 BOREAS trial to the FDA by the end of the ...